<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001513'>Obesity</z:hpo> is an established risk factor for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> is a peroxisome proliferator- activated receptor γ(PPARγ) <z:chebi fb="4" ids="48705">agonist</z:chebi> that induces differentiation in adipocytes and induces <z:mpath ids='MPATH_73'>growth arrest</z:mpath> and/or <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in vitro in several <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we investigated the effect of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> on the development of azoxymethane-induced colon <z:mpath ids='MPATH_557'>aberrant crypt foci</z:mpath> (ACF) in KK-Ay <z:hpo ids='HP_0001513'>obesity</z:hpo> and <z:mp ids='MP_0002055'>diabetes</z:mp> model mice, and tried to clarify mechanisms by which the PPARγ ligand inhibits ACF development </plain></SENT>
<SENT sid="3" pm="."><plain>Administration of 800 ppm <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> reduced the number of colon ACF / mouse to 30% of those in untreated mice and improved hypertrophic changes of adipocytes in KK-Ay mice with significant reduction of serum <z:chebi fb="0" ids="17855">triglyceride</z:chebi> and insulin levels </plain></SENT>
<SENT sid="4" pm="."><plain>Moreover, <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels of adipocytokines, such as leptin, monocyte chemoattractant protein-1 and plasminogen activator inhibitor-1, in the visceral fat were decreased </plain></SENT>
<SENT sid="5" pm="."><plain>PCNA immunohistochemistry revealed that <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> treatment suppressed cell proliferation in the colorectal epithelium with elevation of p27 and p53 gene expression </plain></SENT>
<SENT sid="6" pm="."><plain>These results suggest that <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> prevented <z:hpo ids='HP_0001513'>obesity</z:hpo>-associated colon <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> through improvement of dysregulated adipocytokine levels and high serum levels of <z:chebi fb="0" ids="17855">triglyceride</z:chebi> and insulin, and increase of p27 and p53 <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels in the colorectal mucosa </plain></SENT>
<SENT sid="7" pm="."><plain>These data indicate that <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> warrants attention as a potential chemopreventive agent against <z:hpo ids='HP_0001513'>obesity</z:hpo>-associated <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>